What is the 13F Pro Quality Score for CVS?

13F Pro ranks CVS HEALTH Corp (CVS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CVS's current score at https://13fpro.ai/company/CVS (free sign-up required for the full ranking).

Where does 13F Pro source CVS data?

All CVS HEALTH Corp fundamentals and ownership data come directly from SEC EDGAR. CVS HEALTH Corp files with the SEC under CIK 64803. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CVS in?

CVS HEALTH Corp (CVS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CVS research updated on 13F Pro?

CVS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CVS HEALTH Corp(CVS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 64803 CVS stock profile & AI dashboard →

13F Pro Quality Score

59.4/100

Rank #927 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

52.4/100

Profitability

37.6/100

Balance Sheet

52.2/100

Earnings Quality

90.0/100

Free Cash Flow

35.0/100

Institutional Flow

70.5/100

Revenue Scale

99.8/100

Dilution Risk

87.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CVS Scores 59/100

exact factor attribution · 2026-09-11

CVS's composite is driven by scale and earnings quality, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+7.5 pts

100th pct

Earnings quality

+4.0 pts

90th pct

Shareholder dilution

+1.9 pts

87th pct

Institutional flow

+1.0 pts

71th pct

Revenue growth

+0.5 pts

52th pct

Capital efficiency

+0.2 pts

52th pct

Earnings growth

-1.5 pts

20th pct

Profitability

-1.9 pts

38th pct

Free cash flow

-2.3 pts

35th pct

Latest change (2026-08-05): 51 → 54 · ↑ Capital efficiency 41→51; ↑ Earnings growth 4→27; despite ↓ Revenue growth 55→45

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CVS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CVS HEALTH Corp (CVS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CVS at 59.4/100 on a 32-signal composite quality model, placing it at rank #927 of 2,961 stocks — the top half of the AI-ranked universe. CVS scores in the top quartile across revenue scale (99.8), earnings quality (90.0). Areas of concern include free cash flow (35.0) and profitability (37.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), CVS HEALTH Corp reports quarterly revenue of $106.1B, net income of $3.0B, an operating margin of 4.4%. Top institutional holders of CVS by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, Capital World Investors, based on the most recent SEC filings. CVS trades on the NYSE exchange and files with the SEC under CIK 64803. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CVS HEALTH Corp directly from SEC EDGAR. CVS HEALTH Corp's 13F Pro composite quality score has ranged between 49 and 66 since 2021, currently 59.4 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$106.1B

Net Income

Q2 2026

$3.0B

Free Cash Flow

Q2 2026

$5.7B

Operating Margin

Q2 2026

4.4%

ROIC

Q2 2026

13.3%

D/E Ratio

Q2 2026

0.77

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+7.8% YoY

$402.07BFY 2025

FY22 $322.47BFY23 $357.78BFY24 $372.81BFY25 $402.07B

Net Income

-61.7% YoY

$1.77BFY 2025

FY22 $4.31BFY23 $8.34BFY24 $4.61BFY25 $1.77B

Operating Income

-45.3% YoY

$4.66BFY 2025

FY22 $7.95BFY23 $13.74BFY24 $8.52BFY25 $4.66B

EPS (Diluted)

-62.0% YoY

$1.39FY 2025

FY22 $3.26FY23 $6.47FY24 $3.66FY25 $1.39

Total Assets

+0.1% YoY

$253.54BFY 2025

FY22 $228.28BFY23 $249.73BFY24 $253.22BFY25 $253.54B

Total Debt

-2.6% YoY

$64.57BFY 2025

FY22 $52.25BFY23 $61.61BFY24 $66.27BFY25 $64.57B

Op. Cash Flow

+16.8% YoY

$10.64BFY 2025

FY22 $16.18BFY23 $13.43BFY24 $9.11BFY25 $10.64B

Free Cash Flow

+23.4% YoY

$7.81BFY 2025

FY22 $13.45BFY23 $10.39BFY24 $6.33BFY25 $7.81B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$402.07B +7.8%	$372.81B +4.2%	$357.78B +10.9%	$322.47B +10.4%	$292.11B +8.7%	$268.71B
Net Income	$1.77B -61.7%	$4.61B -44.7%	$8.34B +93.6%	$4.31B -46.1%	$8.00B +11.5%	$7.18B
Operating Income	$4.66B -45.3%	$8.52B -38.0%	$13.74B +72.8%	$7.95B -40.2%	$13.31B -4.3%	$13.91B
EPS (Diluted)	$1.39 -62.0%	$3.66 -43.4%	$6.47 +98.5%	$3.26 -45.8%	$6.02 +10.3%	$5.46
Total Assets	$253.54B +0.1%	$253.22B +1.4%	$249.73B +9.4%	$228.28B -2.0%	$233.00B +1.0%	$230.72B
Total Debt	$64.57B -2.6%	$66.27B +7.6%	$61.61B +17.9%	$52.25B -7.0%	$56.18B -13.1%	$64.65B
Operating Cash Flow	$10.64B +16.8%	$9.11B -32.2%	$13.43B -17.0%	$16.18B -11.4%	$18.27B +15.1%	$15.87B
Free Cash Flow	$7.81B +23.4%	$6.33B -39.1%	$10.39B -22.7%	$13.45B -14.6%	$15.74B +17.3%	$13.43B

Get alerted when CVS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CVS HEALTH Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CVS

BlackRock, Inc.
$12.7B123,223,409 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.6B83,315,369 sh
Capital World Investors
$7.8B74,951,955 sh
STATE STREET CORP
$6.2B60,283,408 sh
DODGE & COX
$5.2B50,012,765 sh
WELLINGTON MANAGEMENT GROUP LLP
$3.5B33,801,113 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.1B29,899,653 sh
FMR LLC
$3.0B28,920,617 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.8B26,637,259 sh
Capital Research Global Investors
$2.5B24,329,151 sh

Fund	Value	Shares
BlackRock, Inc.	$12.7B	123,223,409
VANGUARD CAPITAL MANAGEMENT LLC	$8.6B	83,315,369
Capital World Investors	$7.8B	74,951,955
STATE STREET CORP	$6.2B	60,283,408
DODGE & COX	$5.2B	50,012,765
WELLINGTON MANAGEMENT GROUP LLP	$3.5B	33,801,113
GEODE CAPITAL MANAGEMENT, LLC	$3.1B	29,899,653
FMR LLC	$3.0B	28,920,617
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.8B	26,637,259
Capital Research Global Investors	$2.5B	24,329,151

Companies Similar to CVS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

UNH

UNITEDHEALTH GROUP INC

AI score

Very similar · 39 shared holders

Capital World Investors DODGE & COX Capital Research Global Investors

PFE

PFIZER INC

AI score

Very similar · 42 shared holders

Capital World Investors LSV ASSET MANAGEMENT National Pension Service

ELV

Elevance Health, Inc.

AI score

Very similar · 36 shared holders

Capital International Investors National Pension Service Canoe Financial LP

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 50 shared holders

PZENA INVESTMENT MANAGEMENT LLC LSV ASSET MANAGEMENT Capital International Investors

ABT

ABBOTT LABORATORIES

AI score

Very similar · 37 shared holders

Capital Research Global Investors Capital International Investors National Pension Service

MDT

Medtronic plc

AI score

Very similar · 38 shared holders

Capital Research Global Investors Capital World Investors DODGE & COX

MRK

Merck & Co., Inc.

AI score

Very similar · 45 shared holders

Capital International Investors LSV ASSET MANAGEMENT National Pension Service

ABBV

AbbVie Inc.

AI score

Very similar · 41 shared holders

Capital World Investors Capital Research Global Investors Capital International Investors

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CVS on your watchlist

Track score changes the day CVS HEALTH Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CVS a good stock to buy?

13F Pro's AI-powered analysis of CVS HEALTH Corp (CVS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CVS are available on the CVS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CVS is classified as a large company.

Which hedge funds own CVS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CVS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CVS HEALTH Corp's investment landscape.